| Primary |
| Ischaemic Stroke |
32.1% |
| Acute Myocardial Infarction |
15.5% |
| Product Used For Unknown Indication |
9.4% |
| Pulmonary Embolism |
6.5% |
| Cerebrovascular Accident |
5.6% |
| Retinal Haemorrhage |
4.8% |
| Embolic Stroke |
4.7% |
| Cerebral Artery Occlusion |
2.4% |
| Myocardial Infarction |
2.4% |
| Deep Vein Thrombosis |
2.2% |
| Peripheral Ischaemia |
2.2% |
| Cerebral Infarction |
2.1% |
| Anticoagulant Therapy |
1.7% |
| Thrombotic Cerebral Infarction |
1.5% |
| Age-related Macular Degeneration |
1.3% |
| Intraventricular Haemorrhage |
1.2% |
| Peripheral Arterial Occlusive Disease |
1.2% |
| Antiplatelet Therapy |
1.0% |
| Hypertension |
1.0% |
| Thrombosis |
1.0% |
|
| Death |
36.8% |
| Haemorrhage Intracranial |
7.3% |
| Neurological Decompensation |
5.9% |
| Cerebral Haemorrhage |
5.8% |
| Drug Ineffective |
4.6% |
| Cerebral Infarction |
4.1% |
| Pulmonary Embolism |
4.1% |
| Haemorrhagic Transformation Stroke |
3.6% |
| Myocardial Infarction |
3.1% |
| Vitreous Haemorrhage |
2.7% |
| Haemorrhage |
2.5% |
| Ischaemic Stroke |
2.4% |
| Pneumonia |
2.4% |
| Retinal Detachment |
2.4% |
| Shock |
2.4% |
| Sepsis |
2.2% |
| Angioedema |
2.0% |
| Cerebrovascular Accident |
2.0% |
| Subarachnoid Haemorrhage |
2.0% |
| Reocclusion |
1.9% |
|
| Secondary |
| Product Used For Unknown Indication |
14.9% |
| Acute Myocardial Infarction |
14.7% |
| Ischaemic Stroke |
12.5% |
| Drug Use For Unknown Indication |
10.1% |
| Pulmonary Embolism |
7.7% |
| Retinal Haemorrhage |
6.8% |
| Hypertension |
3.7% |
| Anticoagulant Therapy |
3.3% |
| Thrombolysis |
3.1% |
| Peripheral Ischaemia |
2.9% |
| Off Label Use |
2.6% |
| Cerebrovascular Accident |
2.2% |
| Prophylaxis |
2.2% |
| Thrombosis Prophylaxis |
2.2% |
| Antiplatelet Therapy |
2.0% |
| Deep Vein Thrombosis |
2.0% |
| Acute Myeloid Leukaemia |
1.8% |
| Cerebral Artery Occlusion |
1.8% |
| Cerebral Infarction |
1.8% |
| Embolism Arterial |
1.8% |
|
| Death |
28.4% |
| Haemorrhage Intracranial |
6.9% |
| Intraocular Pressure Increased |
6.9% |
| Cerebral Haematoma |
5.9% |
| Ischaemic Stroke |
5.9% |
| Drug Ineffective |
4.9% |
| Anaphylactoid Shock |
3.9% |
| Endophthalmitis |
3.9% |
| Sepsis |
3.9% |
| Cerebral Haemorrhage |
2.9% |
| Haemorrhagic Transformation Stroke |
2.9% |
| Pulmonary Embolism |
2.9% |
| Shock |
2.9% |
| Upper Gastrointestinal Haemorrhage |
2.9% |
| Urticaria |
2.9% |
| Vascular Pseudoaneurysm |
2.9% |
| Vomiting |
2.9% |
| Angioedema |
2.0% |
| Aphasia |
2.0% |
| Cardiac Valve Prosthesis User |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.8% |
| Drug Use For Unknown Indication |
27.8% |
| Pain |
6.1% |
| Adverse Event |
5.4% |
| Multiple Myeloma |
5.3% |
| Nausea |
3.0% |
| Prophylaxis |
2.5% |
| Constipation |
2.3% |
| Anxiety |
1.7% |
| Plasma Cell Myeloma |
1.6% |
| Hypertension |
1.4% |
| Deep Vein Thrombosis |
1.3% |
| Nuclear Magnetic Resonance Imaging |
1.3% |
| Supplementation Therapy |
1.1% |
| Breast Cancer |
1.0% |
| Gastrooesophageal Reflux Disease |
1.0% |
| Graft Versus Host Disease |
0.9% |
| Anaemia |
0.9% |
| Blood Pressure Abnormal |
0.9% |
| Metastases To Bone |
0.8% |
|
| Vomiting |
8.9% |
| Wound Drainage |
8.9% |
| Venous Occlusion |
7.6% |
| Tricuspid Valve Incompetence |
6.3% |
| Aspartate Aminotransferase Increased |
5.1% |
| Nephrogenic Systemic Fibrosis |
5.1% |
| Pneumonia |
5.1% |
| Sepsis |
5.1% |
| Thrombocytopenia |
5.1% |
| Weight Decreased |
5.1% |
| Neutropenic Sepsis |
3.8% |
| Osteomyelitis |
3.8% |
| Pulmonary Embolism |
3.8% |
| Pyrexia |
3.8% |
| Renal Failure Acute |
3.8% |
| Respiratory Failure |
3.8% |
| Skin Tightness |
3.8% |
| Tumour Lysis Syndrome |
3.8% |
| Vision Blurred |
3.8% |
| Visual Impairment |
3.8% |
|
| Interacting |
| Product Used For Unknown Indication |
33.3% |
| Atrial Fibrillation |
16.7% |
| Cerebrovascular Accident Prophylaxis |
16.7% |
| Hypertension |
16.7% |
| Ischaemic Stroke |
16.7% |
|
| Drug Interaction |
60.0% |
| Ischaemic Stroke |
40.0% |
|
